Patent · US Active

4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication

US11505543B2 · kind B2 · utility

0Cited by

0References

4Claims

0Family size

Assignee

ViiV Healthcare UK (No.5) Limited · GB

Inventors

Makonen Belema · North Haven, US
John A. Bender · Middletown, US
David B. Frennesson · Naugatuck, US
Eric P. Gillis · Cheshire, US
Christiana I. Iwuagwu · Wallingford, US
John F. Kadow · Wallingford, US
B. Narasimhulu Naidu · Durham, US
Kyle E. Parcella · Wallingford, US
Kevin Peese · Haddam, US
Ramkumar Rajamani · Wallingford, US
Mark G. Saulnier · Haddam, US
Alan Xiangdong Wang · Guilford, US
Manoj Patel · Berlin, US
Michael S. Bowsher · Prospect, US

Key dates

Filing date	Apr 11, 2019
Grant date	Nov 22, 2022
Priority date	—
Expiry date	Apr 26, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D413/14
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.